𝐉𝐨𝐢𝐧 𝐘𝐨𝐮𝐫 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚𝐥 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐢𝐧 𝐋𝐨𝐧𝐝𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐!
The inaugural Cell Therapy Analytical Development Summit Europe is the leading industry-defining forum in Europe made exclusively for analytical, CMC, QC, process development and regulatory experts.
Next generation cell therapies are emerging as game changing treatments for cancer and beyond, but given their increasing complexities, developing robust, reliable, and in-depth analytical assays is critical to prove their safety and quality to the regulatory authorities.
This year we have unrivalled content showcasing:
• Efforts to harmonise reference standards for state-of-the-art analytical development
• Regulatory experience case studies to hit guidelines and avoid pushback
• Strategies to develop a successful potency assay to determine product activity
• Process transfers demonstrating analytical robustness and product comparability
• New technology to expand and improve your analytical toolbox
• Development and validation of analytical methods to fulfil GMP guidelines
• Best methods to approach final product characterisation by starting with the end in mind
• Automated technologies for improved accuracy, repeatability and speed
… To provide your team with the lessons learned to achieve success in analytical submissions from IMPD/IND through to the clinic and beyond.
Data and learnings will be shared from key European biopharma stakeholders including Cellectis, Gadeta, GSK, and Sanofi and more to support your efforts in developing efficacious, potent and safe cell therapies. Unite with these companies and more this August to fast-track your pipeline into the clinic and beyond.
23-25 August, 2022
8.30am-5pm BST | London, UK
Drug Developers – Standard Pricing (Earlybird rates & workshops available) GBP 2499.00
Academic – Standard Pricing (Earlybird rates & workshops available) GBP 1999.00
Service Providers – Standard Pricing (Earlybird rates & workshops available) GBP 2899.00
Category: Conferences | Science, Health & Medicine | Pharmaceuticals
Speakers: Assegid Oumie, Principal Scientist, Analytical Development Lead, Enara Bio, Benoit Champluvier, Executive Director, Process & Analytical Development, Cellectis, Eesha Vyas, Regulatory Affairs Manager, Oncology, 𝐆𝐥𝐚𝐱𝐨𝐒𝐦𝐢𝐭𝐡𝐊𝐥𝐢𝐧𝐞, Sharon Longhurst, Vice President of Development, 𝐆𝐚𝐝𝐞𝐭𝐚, Berkan Vural, Cell Analytical Scientist, 𝐆𝐥𝐚𝐱𝐨𝐒𝐦𝐢𝐭𝐡𝐊𝐥𝐢𝐧𝐞, Christopher Bravery, Regulatory Scientist, 𝐈𝐧𝐝𝐞𝐩𝐞𝐧𝐝𝐞𝐧𝐭 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐚𝐧𝐭, Jeetendra Kumar, Specialist R&D, 𝐈𝐦𝐦𝐮𝐧𝐞𝐞𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, Sofia Håkansson Buch, Vice President, Cell Therapy CMC, 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤, Arindam Mitra, Associate Director, CMC, 𝐋𝐞𝐮𝐜𝐢𝐝 𝐁𝐢𝐨, Chaya Mazouz, Vice President, Quality (IL) & Global Regulatory Affairs, 𝐎𝐫𝐠𝐞𝐧𝐞𝐬𝐢𝐬, Driss Chader, Analytical Development Engineer, 𝐂𝐞𝐥𝐥𝐞𝐜𝐭𝐢𝐬, Farzin Farzaneh, Chair of Molecular Medicine, 𝐊𝐢𝐧𝐠’𝐬 𝐂𝐨𝐥𝐥𝐞𝐠𝐞 𝐋𝐨𝐧𝐝𝐨𝐧, Adi Zohar, Quality Control Manager, 𝐏𝐥𝐮𝐫𝐢𝐬𝐭𝐞𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, Ruti Goldberg, Compliance & Methods Validations Manager, 𝐏𝐥𝐮𝐫𝐢𝐬𝐭𝐞𝐦 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, Yvet Noordman, Head of Analytical Development, Bioanalytics Genomic Medicine, 𝐒𝐚𝐧𝐨𝐟𝐢, Hélène Negre, EPFIA Project Leader, 𝐓𝟐𝐄𝐯𝐨𝐥𝐯𝐞 𝐈𝐌𝐈 𝐂𝐨𝐧𝐬𝐨𝐫𝐭𝐢𝐮𝐦, 𝐒𝐞𝐫𝐯𝐢𝐞𝐫, Mohamad Toutounji, ADQC Scientist, Cell Therapy, 𝐒𝐚𝐧𝐨𝐟𝐢, Terri Gaskell, Chief Technology Officer, 𝐑𝐢𝐧𝐫𝐢 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, Emilio Cosimo, Product Development Manager, 𝐓𝐂 𝐁𝐢𝐨𝐏𝐡𝐚𝐫𝐦, Katherine Cornish, Senior Stem Cell Biologist, Head of Cell Therapy, 𝐔𝐊 𝐒𝐭𝐞𝐦 𝐂𝐞𝐥𝐥 𝐁𝐚𝐧𝐤, 𝐍𝐈𝐁𝐒𝐂, Therese Choquette, Head of Analytical Science, 𝐓𝐢𝐠𝐞𝐧 𝐏𝐡𝐚𝐫𝐦𝐚